Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Acquisitions & Divestments (2016 - 2023)

Historic Change in Acquisitions & Divestments for Seres Therapeutics (MCRB) over the last 9 years, with Q2 2023 value amounting to $11.8 million.

  • Seres Therapeutics' Change in Acquisitions & Divestments fell 6497.14% to $11.8 million in Q2 2023 from the same period last year, while for Mar 2024 it was $11.8 million, marking a year-over-year decrease of 8908.25%. This contributed to the annual value of $23.0 million for FY2023, which is 8363.85% down from last year.
  • According to the latest figures from Q2 2023, Seres Therapeutics' Change in Acquisitions & Divestments is $11.8 million, which was down 6497.14% from $11.2 million recorded in Q1 2023.
  • In the past 5 years, Seres Therapeutics' Change in Acquisitions & Divestments ranged from a high of $54.8 million in Q2 2021 and a low of $2.5 million during Q3 2020
  • Its 5-year average for Change in Acquisitions & Divestments is $27.3 million, with a median of $22.4 million in 2020.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 165398.23% in 2021, then crashed by 7451.56% in 2023.
  • Seres Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $16.9 million in 2019, then grew by 1.68% to $17.2 million in 2020, then surged by 154.03% to $43.6 million in 2021, then tumbled by 50.81% to $21.5 million in 2022, then crashed by 45.27% to $11.8 million in 2023.
  • Its last three reported values are $11.8 million in Q2 2023, $11.2 million for Q1 2023, and $21.5 million during Q4 2022.